Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Secondary Prevention: Aspirin Combined With Dipyridamole Just As Effective As Clopidogrel; Endarterectomy Safer Than Angioplasty
In the area of secondary prevention as well - guarding against renewed events in patients who already suffered from a stroke or a TIA - Professor Ferro points to important new research: "In this patient population, the direct comparison between Clopidogrel and the combination of aspirin with extended release Dipyridamole did not reveal any difference between both strategies." Both approaches have proven to be slightly more effective than aspirin alone.
generic viagra online
Insmed Announces Results Of IPLEX(TM) Phase II Trial In Myotonic Muscular Dystrophy
Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, announced results from its exploratory U.S. Phase II clinical trial evaluating IPLEX(TM) (mecasermin rinfabate) in patients with myotonic muscular dystrophy ("MMD"). The randomized, double-blind, placebo-controlled Phase II trial conducted in 13 centers across the U.S. enrolled 69 patients with MMD, for a six-month period. As this was an exploratory trial, a primary endpoint was not pre-defined. The trial explored measures of endurance, using the six-minute walk test, muscle function and strength, cognitive function, gastrointestinal function, pain, quality of life, insulin sensitivity, lipid metabolism, and safety and tolerability of IPLEX(TM).
News of the day
Mixed Neurodegenerative Disorders Are Emerging From The Shadows
Many cases of age-related neurodegenerative disease fall into the gray zone between big, defined diseases - Alzheimer"s or Parkinson"s, for example. Their diagnostic accuracy is low, researchers agree. That"s a problem, because mixed disease is not only common, but also quite different in its course from pathologically "pure" disease. (Mixed disease is often worse.) But there"s also excitement and opportunity. The large overlap between established neurodegenerative diseases is ripe for scientific exploration, and recent advances at the genetic, clinico-pathologic, and molecular levels have turned it into a dynamic area of research. In particular, diseases such as Dementia with Lewy bodies and frontotemporal dementias are drawing intense interest as biomarker development branches out beyond Amyloid beta and tau, holding out a future where molecular-based diagnoses can define the pathogenic proteins that together drive a given person"s individual disease.
Health Insurance

Higher Levels Of A Certain Protein Associated With Lower Risk Of Type 2 Diabetes

Persons with higher levels of adiponectin, a protein that is produced by fat cells and that has anti-inflammatory and insulin-sensitizing properties, have an associated lower risk of type 2 diabetes, according to an analysis of previous studies, reported in the July 8 issue of JAMA. Some studies have suggested several mechanisms through which adiponectin may decrease the risk of type 2 diabetes, although the strength and consistency of the relation between plasma adiponectin and risk of type 2 diabetes has been unclear, according to background information in the article. Shanshan Li, M.D., M.Sc., of the Harvard School of Public Health, Boston, and colleagues conducted a review and meta-analysis to assess the consistency of the association of adiponectin levels and risk of type 2 diabetes. The researchers identified thirteen studies with a total of 14,598 participants and 2,623 new cases of type 2 diabetes that met criteria for inclusion in the meta-analysis. The authors found that higher adiponectin levels were associated with a lower risk of type 2 diabetes. This inverse association was consistently observed in whites, East Asians, Asian Indians, African Americans and Native Americans. The results did not differ substantially by method of diabetes ascertainment, study size, follow-up duration, body mass index or proportions of men and women. "Although these epidemiologic studies cannot establish causality, the consistency of the association across diverse populations, the dose-response relationship, and the supportive findings in mechanistic studies indicate that adiponectin is a promising target for the reduction of risk of type 2 diabetes," the authors write. The researchers add that recent studies have shown that adiponectin levels can be increased through pharmaceutical and lifestyle interventions. "In addition, adiponectin levels may be useful for identifying persons likely to benefit most from interventions to treat "dysfunctional adipose tissue" and its metabolic complications. Future studies should also evaluate whether adiponectin is useful for prediction of type 2 diabetes in addition to established risk factors using statistical techniques appropriate for prognostic analyses." JAMA. 2009;302[2]:179-188. Journal of the American Medical Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009